-
The pharmaceutical industry is pushing for intelligent transformation to improve production efficiency and product quality
Time of Update: 2022-04-15
From the above point of view, through the implementation of intelligent transformation, pharmaceutical companies can achieve cost reduction and efficiency improvement, which has become an important starting point for promoting the high-quality development of the pharmaceutical industry .
-
The development of the traditional Chinese medicine formula granule industry has entered a new stage, and the transformation and upgrading of pharmaceutical enterprises is urgent
Time of Update: 2022-04-15
In recent years, with the enhancement of residents' awareness of health care, the continuous release of policy dividends, and the active deployment of a large number of enterprises, the market of traditional Chinese medicine granules has maintained a rapid growth trend .
-
Under the new policy of medical reform, pharmaceutical distribution enterprises have accelerated their transformation!
Time of Update: 2022-04-15
The company has stated that under a clear development strategy, around the goal of improving value to increase market value, standardize operations, adhere to the concept of "performance is king" and further promote enterprise transformation and innovation, continue to optimize business models and profitability, and improve.
-
In 2024, the traditional Chinese medicine market may exceed 1 trillion yuan!
Time of Update: 2022-04-15
At the same time, the investment of traditional Chinese medicine companies in the research and development of new drugs has also continued to increase .
-
This pharmaceutical stock hit the daily limit again, gaining 6 boards in 8 days!
Time of Update: 2022-04-15
Affected by this news, from March 2nd to 4th, Sinopharm had the daily limit for three consecutive trading days .
It is worth mentioning that on March 11, affected by the news of the cooperation between China Pharmaceuticals and Pfizer, Changjiang Health and Peking University Pharmaceuticals also increased their daily limit.
-
Pharmaceutical companies have embarked on the road of innovation, and these pain points may become "stumbling blocks"
Time of Update: 2022-04-15
According to the industry, the investment of large pharmaceutical companies in drug innovation has been increasing in recent years, but there are still very few new drugs that can enter the market every year, and the number of failed new drug R&D projects is still increasing day by day .
-
The traditional Chinese medicine sector is active again, and stocks such as Longjin Pharmaceutical have opened their daily limit
Time of Update: 2022-04-15
The third quarterly report shows that in the first three quarters of 2021, the company's main income was 969 million yuan, a year-on-year increase of 4.
Shanghai Kaibao is a comprehensive pharmaceutical company mainly engaged in the R&D, production and sales of modern Chinese medicines .
-
14 domestic class 1 new drugs are coming!
Time of Update: 2022-03-09
Sales of some ALK inhibitors in Chinese public medical institutions and physical pharmacies in Chinese cities in 2020 (unit: 10,000 yuan) Source: Minet database Innovative Drug One Brother, the first new drug introduced by Hengrui Medicine, known as "Innovative Drug One Brother" Hengrui Medicine, known as Hengrui Medicine, currently has 10 innovative drugs (9 category 1 new drugs) approved for marketing in China, of which anti-tumor drugs account for "half of the country" .
-
The "water seller" collapsed!
Time of Update: 2022-03-09
S. Department of Commerce had a set of routine verification procedures for the reasonable use of these products (that is, for personal use, not for resale), but in the past two years due to the impact of the new crown pneumonia epidemic, it could not be completed in time, which led WuXi Biologics to enter the UVL .
-
"Rising" has become a hot word of the year, and these traditional Chinese medicine companies have received attention
Time of Update: 2022-03-09
Comments: The raw materials of traditional Chinese medicine have been put on the cloak of capital, and the price changes have largely been separated from their real value .
-
Burnet prices rose slightly, and the weak inventory pushed the market to continue to rise!
Time of Update: 2022-03-09
Years ago, there were not many supplies in the market, and the price fluctuated slightly, but the overall attention was not high .
-
The latest results of a group of pharmaceutical companies listed on the Science and Technology Innovation Board are announced
Time of Update: 2022-03-09
Among them, BeiGene, with a market value of 100 billion, has become the first listed pharmaceutical company in 3 places, with a total R&D expenditure of more than 20 billion yuan in the past 4 years; 6 companies, including Nuohezhiyuan, Nanowei Technology, and Jiahe Meikang, are expected to increase their net profit in 2021.
-
The three major varieties are out, and the top 10 best-selling drugs in 2022 will undergo great changes!
Time of Update: 2022-03-09
The biological targeting agent Dabitux may rank among the top 10 best-selling drugs in the world for the first time this year with a gratifying sales growth rate, while the anticoagulants Xarelto/Xarelto (rivaroxaban) and small molecules, which were at the bottom last year The BTK inhibitor Yike/Imbruvica (ibrutinib) and the ophthalmic biologic drug Aliya/Eylea (aflibercept), which are about to be impacted by biosimilars, were tragically eliminated .
-
Six key words in the new stage of centralized procurement!
Time of Update: 2022-03-09
At the beginning of the new year, centralized procurement with volume is still an important starting point for the new medical reform, especially the "three medical linkage" reform with medical insur
-
Annual performance PK of multinational pharmaceutical companies!
Time of Update: 2022-03-09
Pfizer: New crown vaccine + oral drugs drive performance soaring Pfizer CEO Albert Bourla said that Pfizer’s sales in 2021 are expected to exceed $80 billion, the highest annual figure ever .
-
Centralized hanging network, inter-provincial joint procurement, centralized procurement of traditional Chinese medicine formula granules is approaching!
Time of Update: 2022-03-09
According to the industry, since proprietary Chinese medicines have been included in volume procurement, the profit margins of the entire proprietary medicines have been greatly reduced, and most of the traditional Chinese medicines are covered by medical insurance reimbursement, resulting in a large number of medicines that were originally used for clinical promotion The representative turned to high-end Chinese herbal decoction pieces and formula granules .
-
Fujian announces the third batch of medical insurance key monitoring drugs and the list of key drugs
Time of Update: 2022-03-09
24), with the approval of the Provincial Medical Insurance Bureau, the "Third Batch of Medical Insurance Key Monitoring Drugs List" and the "Third Batch of Medical Insurance Focused Drug List" to be announced .
-
Guangxi promotes "going out" of traditional Chinese medicine and builds a joint laboratory with ASEAN
Time of Update: 2022-03-08
Guangxi Zhuang Autonomous Region Traditional Chinese Medicine Administration introduced on the 7th that during the "14th Five-Year Plan" period, Guangxi will implement the open cooperation project of traditional Chinese medicine Zhuang Yao medicine, promote the construction of Guangxi-ASEAN traditional medicine research and development center, and cooperate with ASEAN countries to build a joint laboratory .
-
Stock price dives, R&D burns money, biopharmaceutical companies move forward tenaciously in 2021
Time of Update: 2022-03-08
Strong research and development strength is more favored by capital Wind data shows that from 2018 to 2020, A-share biopharmaceutical companies invested an average of 296 million yuan in research and development each year, much higher than the 146 million yuan of the entire pharmaceutical industry .
-
A blockbuster medical law will go into effect, affecting doctors across the country
Time of Update: 2022-03-08
At the meeting, Xu Yucai, a well-known medical reform expert, explained the multi-point practice policy of doctors in the era of physician law for more than a thousand guests from all over the country .
